Biocon and Biomm ink exclusive deal to bring Semaglutide to Brazil
Biocon Limited (BSE code: 532523, NSE: BIOCON), a leader in global biopharmaceutical innovations, has announced a pivotal licensing and supply agreement with Brazil’s Biomm S.A., a specialty pharmaceutical company, to commercialize Semaglutide, a drug aimed at enhancing glycemic control in adults with type-2 diabetes. This exclusive partnership allows Biocon to handle the development, manufacturing, and […]